A few more and less known facts about dydrogesterone Review article
Article Sidebar
Published:
Jun 30, 2023
Keywords:
hormone therapy, dysmenorrhea, fetal defects, premenstrual syndrome
Main Article Content
Abstract
Dydrogesterone was introduced into medicine in the early 1960s. Since that time many studies confirming its effectiveness in various indications, including threatened or recurrent miscarriage, menstrual problems, infertility treatment, endometriosis symptoms and hormone therapy for menopausal symptoms. Despite a large amount of information about using dydrogesterone, many unproven beliefs have been accumulated around it. This resulting in unjustified restrictions on the use of this drug. In this work they will be analyzed and verified.
Article Details
How to Cite
Miotła, P. (2023). A few more and less known facts about dydrogesterone. Medycyna Faktow (J EBM), 16(2(59), 177-182. https://doi.org/10.24292/01.MF.0223.08
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ott J, Egarter C, Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol Endocrinol. 2022; 38(4): 279-87. http://doi.org/10.1080/09513590.2021.2016692.
2. Charakterystyka Produktu Leczniczego. Luteina (access: 21.03.2023).
3. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev. 2009; 85(6): 375-7.
4. ClinicalTrials.gov. Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI (access: 21.03.2023).
5. Stanczyk FZ, Hapgood JP, Winer S et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34: 171-208.
6. Kurzawa R, Czyżyk A, Kuczyński W et al. Stanowisko grupy ekspertów dotyczące wsparcia fazy lutealnej w przypadku stosowania technik rozrodu wspomaganego (2020) (access: 22.03.2023).
7. Chan DMK, Cheung KW, Ko JKY et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double- blind controlled trial. Hum Reprod. 2021; 36: 587-95.
8. Siew JYS, Allen JC, Hui CYY et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018; 228: 319-24.
9. Atzmon Y, Aslih N, Estrada D et al. Comparable outcomes using oral dydrogesterone vs. micronized vaginal progesterone in frozen embryo transfer: a retrospective cohort study. Reprod Sci. 2021; 28: 1874-81.
10. Ozer G, Yuksel B, Yucel Cicek OS et al. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021; 50(5): 102030.
11. Tomic V, Tomic J, Klaic DZ et al. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015; 186: 49-53.
12. Nadarajah R, Rajesh H, Wong KY et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017; 58(6): 294-7.
13. Tournaye H, Sukhikh GT, Kahler E et al. A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5): 1019-27.
14. Griesinger G, Blockeel C, Sukhikh GT et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018; 33: 2212-21.
15. Huang J, Xie Q, Lin J et al. Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin- primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019; 13: 2553-63.
16. Tausk M. A general summary of dydrogesterone, a derivative of retroprogesterone. Tausk M (ed). International Encyclopaedia of Pharmacology and Therapeutics. Section 48, Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs. Vol. II. Pergamon Press, Oxford, New York 1972: 481.
17. Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016; 32(2): 97-106.
18. Ikeda T, Suzuki Y, Maeda T et al. Analysis of dysmenorrhea-associated factors and relaxation methods in highschool students. Bosei Eisei. 2011; 52: 129-38.
19. Bernardi M, Lazzeri L, Perelli F et al. Dysmenorrhea and related disorders. F1000Res. 2017; 6: 1645.
20. Taniguchi F, Ota I, Iba Y et al. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: an open-label multicenter clinical study. J Obstet Gynaecol Res. 2019; 45: 168-75.
2. Charakterystyka Produktu Leczniczego. Luteina (access: 21.03.2023).
3. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev. 2009; 85(6): 375-7.
4. ClinicalTrials.gov. Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI (access: 21.03.2023).
5. Stanczyk FZ, Hapgood JP, Winer S et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34: 171-208.
6. Kurzawa R, Czyżyk A, Kuczyński W et al. Stanowisko grupy ekspertów dotyczące wsparcia fazy lutealnej w przypadku stosowania technik rozrodu wspomaganego (2020) (access: 22.03.2023).
7. Chan DMK, Cheung KW, Ko JKY et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double- blind controlled trial. Hum Reprod. 2021; 36: 587-95.
8. Siew JYS, Allen JC, Hui CYY et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018; 228: 319-24.
9. Atzmon Y, Aslih N, Estrada D et al. Comparable outcomes using oral dydrogesterone vs. micronized vaginal progesterone in frozen embryo transfer: a retrospective cohort study. Reprod Sci. 2021; 28: 1874-81.
10. Ozer G, Yuksel B, Yucel Cicek OS et al. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021; 50(5): 102030.
11. Tomic V, Tomic J, Klaic DZ et al. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015; 186: 49-53.
12. Nadarajah R, Rajesh H, Wong KY et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017; 58(6): 294-7.
13. Tournaye H, Sukhikh GT, Kahler E et al. A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5): 1019-27.
14. Griesinger G, Blockeel C, Sukhikh GT et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018; 33: 2212-21.
15. Huang J, Xie Q, Lin J et al. Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin- primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019; 13: 2553-63.
16. Tausk M. A general summary of dydrogesterone, a derivative of retroprogesterone. Tausk M (ed). International Encyclopaedia of Pharmacology and Therapeutics. Section 48, Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs. Vol. II. Pergamon Press, Oxford, New York 1972: 481.
17. Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016; 32(2): 97-106.
18. Ikeda T, Suzuki Y, Maeda T et al. Analysis of dysmenorrhea-associated factors and relaxation methods in highschool students. Bosei Eisei. 2011; 52: 129-38.
19. Bernardi M, Lazzeri L, Perelli F et al. Dysmenorrhea and related disorders. F1000Res. 2017; 6: 1645.
20. Taniguchi F, Ota I, Iba Y et al. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: an open-label multicenter clinical study. J Obstet Gynaecol Res. 2019; 45: 168-75.